Novo Nordisk touts blockbuster diabetes data; Gilead lung drug disappoints; Cephalon names Buchi CEO;

@FierceBiotech: Vertex trims a telaprevir study from its slate of hep C work. News | Follow @FierceBiotech

> Novo Nordisk is touting the promising results of two late-stage trials of its experimental diabetes drug Degludec. Analysts estimate the Degludec franchise could generate more than $2 billion in annual sales. Story

> Gilead has halted a clinical trial of its lung drug ambrisentan after an interim analysis showed it was not effective for IPF. The news came as no great surprise. Article

> Cephalon says that J. Kevin Buchi has officially been named CEO in the wake of Frank Baldino's recent death. News

> Gold-plated liposomes an anti-cancer stocking stuffer. Story

And Finally... H. Lundbeck is wrapping trials of nalmafene, which could go on to become the first new treatment of alcoholism Europe's seen in 15 years. Report

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.